Fundraising Fox

George Medicines

2 known investors

George Medicines develops single-pill combination therapies for cardiometabolic diseases such as hypertension and diabetes, leveraging research from The George Institute for Global Health. The company targets patients with low medication adherence and aims to reduce the burden of non-communicable diseases on patients, families, and health systems.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

MMMark Mallon
Mark MalloninChief Executive Officer
PA
Professor Anthony RodgersChief Medical Officer
DKDr Karl Roberts
Dr Karl RobertsinChief Operating Officer

Investors · 2

Brandon BioCatalyst✓ verifiedMelbourne
Brandon Capital Partnersreported

In the news

George Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreement - BioSpacebiospace.com · Mar 2026Potential of George Medicines’ novel, low-dose, triple combination pill to transform management of hypertension highlighted at global congressfinance.yahoo.com · Sep 2024George Institute Businesses Set for New Multi-Million Dollar Investment to Target Global Health Challenges - BioSpacebiospace.com · Mar 2020

Frequently asked questions

What does George Medicines do?
George Medicines develops single-pill combination therapies for cardiometabolic diseases such as hypertension and diabetes, leveraging research from The George Institute for Global Health. The company targets patients with low medication adherence and aims to reduce the burden of non-communicable diseases on patients, families, and health systems.
Who are George Medicines's investors?
George Medicines's investors include Brandon BioCatalyst, Brandon Capital Partners.